drug
(hyaluronidase (recombinant, human) + nivolumab)
Marketedupdated 6mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.
indications
investigational
NSCLCMelanoma
all catalysts(5)
approval · 5
Dec 27, 2024
approval
$BMY62.93-0.79%
OPDIVO QVANTIG (NIVOLUMAB) — FDA approval
(hyaluronidase (recombinant, human) + nivolumab)
→
May 23, 2025
approval
$BMY62.93-0.79%
OPDIVO QVANTIG (NIVOLUMAB) — FDA approval
(hyaluronidase (recombinant, human) + nivolumab)
→
Oct 27, 2025
approval
$BMY62.93-0.79%
OPDIVO QVANTIG (NIVOLUMAB) — FDA approval
(hyaluronidase (recombinant, human) + nivolumab)
→
Oct 27, 2025
approval
$BMY62.93-0.79%
OPDIVO QVANTIG (NIVOLUMAB) — FDA approval
(hyaluronidase (recombinant, human) + nivolumab)
→
Nov 24, 2025
approval
$BMY62.93-0.79%
OPDIVO QVANTIG (NIVOLUMAB) — FDA approval
(hyaluronidase (recombinant, human) + nivolumab)
→
News(3)
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 18d ago
- Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsBMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.biospace · 2mo ago
- Medicare drug price rule may target under-the-skin Keytruda and OpdivoFor 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.biopharma_dive · 5mo ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that